What Exactly Is Endometriosis��

Chronic pelvic pain, agonising periods, painful intercourse and infrequently infertility are just a few symptoms impacting approximately 170 million women, Endometriosis is an enormous public health crisis. Research from the University of York in 2024 has shown that the average time to diagnose Endometriosis is 6.6 years and women in the United Kingdom have waited nearly 27 years.��

What are the Symptoms of Endometriosis?

Endometriosis presents in many different ways. The NHS outlines that symptoms can range in severity and does not reflect the stage of the condition. People can experience severe pain, while some may not experience symptoms at all. Most commonly, there are period pains that are beyond the threshold of normal cramping. The pain can be so intense that it obstructs the performance of daily activities. Pelvic pain, which may be present during and even outside of the menstrual cycle is another common pain experienced.

Commonly Reported Symptoms of Endometriosis

Endometriosis can have a range of symptoms, from heavy and painful periods, to back pain and much more. Other commonly reported symptoms include:

• Heavy or irregular periods, sometimes requiring frequent changes of pads or tampons
• Pain during or after sex
• Pain when urinating or during bowel movements, particularly during a period
• Lower back or abdominal pain
• Extreme tiredness or fatigue
• Digestive symptoms, such as bloating, diarrhoea or constipation during menstruation
• Difficulty getting pregnant, as endometriosis can sometimes affect fertility��

The NHS also mention that there is still no known cause of����endometriosis and there are currently no treatments that can cure it.

Why Is It So Hard to Diagnose?

For a long time, the only conclusive way to diagnose endometriosis was through laparoscopy, which is a type of surgery. Endometriosis cannot be confirmed with a simple blood test or a scan. However, the problem is not only biological, it is also cultural. Women’s pain has been trivialised, normalised and dismissed over time. ‘Period pain is just part of being a woman‘… so we have all heard before. Cramping is a reason to take a pain killer and carry on.

Doctors keep women’s conditions ‘hiding in plain sight’. Women have been pushed to see their GP for years and have their pain dismissed, misdiagnosed or just written off as having IBS or anxiety, basically ��as a medical mystery.��

What Has the Tech Industry Done?

The FemTech sector has only scant attention, and it has only recently begun to develop in the last 10 years or so. That is decades after the revolution of personal computing and decades after the internet revolutionised everything else. Male bias has persisted in medical research for far too long. Most research literature covers male anatomy, while viewing female anatomy as a side variation. Meanwhile, much of the clinical research that exists excludes women, so all of the drugs, diagnostics and devices developed leave out half the population. When foundational science is incomplete, the technology grounded in it will also be incomplete.

What Has Changed and Why Now?

The good news is that something has shifted. It’s not a single moment but a convergence, of louder patient advocacy, more women in tech and medicine and a growing recognition that women’s health is not a niche market but an enormous, underleveraged opportunity. The WHO published its first-ever fact sheet on endometriosis only in 2021. That’s not a typo. 2021. For a condition affecting one in ten women of reproductive age globally, formal recognition at the world’s foremost health body arrived remarkably late. But it did arrive and with it, a signal that the tide was turning.

How Social Media is Helping

Women have taken to social media to speak about their experience with the condition. This has resulted in the creation of a social media community around endometriosis. These communities have resulted in social media pressure towards change.��

What is The Impact of Endometriosis

The impact of endometriosis in the UK is not only psychological and emotional, but also financial. It is no surprise as it is a condition that affects approximately 1.5 million women. Research by Endometriosis UK states that endometriosis costs the UK economy approximately 8.2 billion pounds annually, which includes both direct and indirect costs of the condition, such as the costs of healthcare services, loss of productivity and decreased participation in the workforce.

Huge Market Opportunity for FemTech

Due to the high rates of Endometriosis and such a large number of the female population affected, this results in a considerable economic opportunity for:

• AI-powered diagnostic solutions
• Imaging and biomarker diagnostics
• Digital symptom tracking
• Hormonal and non-hormonal therapeutics
• Pain management solutions

Historically, the field has been underfunded and has been described by investors as a “white space” in healthcare innovation with considerable economic opportunity.

What is Tech Actually Doing About It Now?

The good news is that innovation is finally catching up. A new wave of startups is attacking the diagnostic delay problem from multiple angles and the approaches are genuinely exciting.

In the UK, a startup called Revela recently raised pre-seed funding to develop AI-powered software that analyses ultrasound scans for signs of endometriosis. The technology aims to flag subtle markers earlier in the diagnostic pathway, giving clinicians better information before they even consider surgery.

The post Why Has It Taken So Long for Tech to Take Endometriosis Seriously? appeared first on 91̽��.

What started as a niche sector focused on women’s health has evolved into a huge industry helping people track, manage and optimise their bodies.

According to Fortune Business Insights, the global femtech market was valued at $9.12 billion in 2025, and it isn’t showing signs of slowing down.

In fact, according to Dealroom, 9 femtech unicorns now exist around the world, with North America and EMEA leading the charge.

What Does FemTech Mean?

FemTech (or female technology) is a term coined by Clue founder Ida Tin, and includes any tech-driven product, software or service that focuses on women’s health. This could cover areas like menstrual health, fertility, menopause, pregnancy, sexual wellness and more.

Whilst FemTech started as a relatively niche sector, even mainstream tech companies are now cashing in on the action, developing apps, wearables and devices to help women optimise their health.

So as the industry grows and evolves, the real question is: who is driving it?

Here, we look at the biggest femtech funding rounds in 2025, showing the startups truly revolutionising women’s health.

Oura: $900 million (October)

Back in October, Oura announced that it has raised over $900 million in a Series E funding round, marking one of the biggest raises in the FemTech space.

Whilst not specifically a FemTech company, Oura’s technology is able to measure basal body temperature and track menstruation, helping women more easily measure their vitals.

Round: Series E

Post-Raise Valuation: $11 billion

Led by: Fidelity Management & Research Company

Tubulis: €344 million (October)

In late 2025, German biotech startup Tubulis raised €308 million in October and then closed a second round to reach a total of €344 million within the same month.

Tubulis are setting out to develop an antibody drug specifically designed to target an antigen that is expressed in ovarian cancer and lung adenocarcinomas. Whilst Tubulis isn’t technically only a femtech company, their research into ovarian cancer will change the lives of women around the world.

Round: Series C

Led by:��Ventock

Future Family: $400 million (April)

Future Family is a company setting out to help couples afford fertility treatments. As current options are incredibly expensive, Future Family provides low-interest loans for treatments like IVF and egg freezing, as well as online support to help couples throughout the process.

Round: Financing

Led by: Clear Haven Capital Management

Hims & Hers: $1 billion (June)

Hims & Hers, a telehealth platform known for its direct-to-consumer approach to wellbeing and health, raised a round of debt financing to help with international expansion, even better personalisation and to boost investment in AI.

Currently Hims & Hers splits products into those for men and those for women. The Hers platform focuses on women’s health, particularly in areas like skin care, birth control and sexual health.

Round: Debt financing

Conceivable Life Sciences: $50 million (September)

Conceivable Life Sciences is setting out to make IVF more effective using AI and robotic precision.

Currently, the IVF cycle is very manual, meaning there is a certain degree of human error. Through their AI platform Aura, Conceivable is setting out to make the process more precise and reliable, by finding the best sperm, eggs and incubation environment. Through the latest fundraise, they are hoping to expand their research and improve IVF outcomes for couples around the world.

Round: Series A

Led by: ARTIS ventures, Stride and ACME ventures.

Mercy BioAnalytics: $59 million (September)

Mercy BioAnalytics is a company that is working on early cancer detection, with a specific focus on blood-based ovarian and lunch cancer tests.

Through their latest funding round, they are setting out to make early detection of ovarian cancer easier. Currently, ovarian cancer is one of the harder ones to diagnose, with many diagnoses happening too late. With their new research, Mercy BioAnalytics is setting out to change this.

Round: Series B

Post-Raise Valuation:��

Visby Medical: $55 million (June)

Visby Medical announced a $55 million raise in order to release its at home STI test for women, which has recently been FDA approved.

The company is setting out to empower women with reliable, lab-grade tests from the comfort of their homes, starting with their STI test.

Round: Financing

Led by: Catalio Capital Management

Diana Health: $55 million (September)

Diana Health is a network of women’s health practices that partners with hospitals to provide personalised care. As part of the round, Diana Health is looking to expand both in-person and online.

Launched in 2020, Diana operates its health programmes in labour and women’s health clinics, partnering with clinicians to provide more holistic care.

Round: Series C

Led by:��HealthQuest Capital

The post The Biggest FemTech Funding Rounds Of 2025 appeared first on 91̽��.

In fact, according to The Data City, the UK’s femtech industry attracted over £480 million in investment funding, growing at a rate of 30%.

And as 2026 rolls around, it doesn’t look like the sector is slowing down anytime soon.

What Actually Is FemTech?

Femtech, or female technology, refers to tech, products and services designed around women’s biology. This could be in regards to reproductive health, fertility, menopause, maternal care or general wellness.

The aim of femtech is to give women better insights into their bodies and bring more attention and investment to women’s health, an area that was historically overlooked.

So, what does 2026 have in store for femtech? To find out we asked the experts…

The Experts

• Anastasia Shubareva-Epshtein, Founder at Carea
• Justyna Strzeszynska, Founder at Joii
• Kristina Simmons, Founder and Managing Partner at Overwater Ventures
• Charlotte Lewis, Principal Associate at Mills & Reeve
• Alisa Sydow, Associate Professor Entrepreneurship at ESCP Business School
• Dr Laura Geige, Medical Director at It’s Me & You
• Sophie Bruce, Founder and CEO at MOLO
• Nancy Scotford, Co-Founder at Get Rude
• Sonja Rincón, CEO and Co-Founder at Menotracker
• Ariane Marie, Founder in FemFinTech

For any questions, comments or features,��please contact us directly.

Anastasia Shubareva-Epshtein, Founder at Carea

“It is an incredibly exciting moment to be innovating in FemTech. My prediction for 2026 is a major shift toward personalisation and genuinely women-centred design. Women are increasingly frustrated with apps, wearables and health solutions that rely on data models built for men. One of my favourite quotes from Dr Stacy Sims is that ‘women are not little men’, a reminder we still need to repeat given that women were only included in clinical research from the mid-1990s onward.

“But things are finally changing. I am seeing more products created with women’s hormonal rhythms as the starting point rather than an afterthought. In 2026, consumers will expect an even deeper level of personalisation, and advances in AI will make this possible. Digital tools and medical devices will be able to provide care that reflects a woman’s own biology and daily experience, helping to ease the pressure on our already stretched healthcare system.

“I am also thrilled to see the growth of sustainable innovation. Menstrual and pregnancy related products were traditionally wasteful and single use, yet we now have the chance to redesign them so they are reusable, environmentally conscious and even able to deliver valuable biomarkers that can help us further personalise the care we provide.”

Justyna Strzeszynska, Founder at Joii

“2026 will be the year that women’s health finally moves away from vague symptom tracking and towards objective, measurable data. Across FemTech, we’ll see a clear shift toward biomarker-driven tools in menstrual health, fertility, menopause and endocrine conditions, because the sector is collectively realising that women have been asked to self-report symptoms for decades without meaningful clinical metrics.

“AI will accelerate this shift. Not in a sci-fi, ‘AI will diagnose everything’ way, but in a practical way by analysing patterns, quantifying change and giving clinicians actual evidence rather than guesswork. A lot of this momentum is coming from the growing acknowledgement that there’s a major gender data gap, and women’s health desperately needs more high-quality datasets to close it.

“Within that broader movement, menstrual blood will become one of the most important, and long overdue, sources of women’s health insights. We’ll move beyond labels like ‘light, medium, heavy’ into measurable bleeding metrics, including actual volume, clot size, flow characteristics and trends across cycles. Menstrual blood will start being recognised as a completely untapped diagnostic fluid, with relevance for heavy bleeding, anaemia, fibroids, adenomyosis, suspected endometriosis and more.

“Period products will evolve too and they’ll stop being passive absorbents and start becoming data-enabled health touchpoints. By 2026, using your period as a long-term health data point won’t feel unusual. It will feel like the natural next step in closing the evidence gap in women’s health.”

Kristina Simmons, Founder and Managing Partner at Overwater Ventures

“Advances in biology, AI, and automation are transforming women’s health from a niche into one of the most technically ambitious sectors in healthcare. What used to be framed as “femtech” will increasingly be understood as core infrastructure for human health, reproduction, and longevity.

“Breakthrough platforms in molecular sensing, cell engineering, and embryology automation will shift women’s health from reactive care to predictive, continuous insight.

“Longevity science and reproductive science will converge, with new therapies targeting menopause, ovarian aging, and hormone-driven cellular decline.

“Robotics and AI will streamline complex workflows in fertility and reproductive medicine, enabling higher precision, lower cost, and global accessibility.

“Investors and healthcare systems will treat women’s health as a foundational pillar of population health, not a consumer segment, as technical rigor and clinical outcomes rise.

“Potential for multiple billion dollar companies to be built.”

For any questions, comments or features,��please contact us directly.

Charlotte Lewis, Principal Associate at Mills & Reeve

“Femtech, coined in 2016 by Ida Tin, refers to technology-driven innovation in women’s health. Once a niche, it is now a fast-growing sector projected to hit $75 billion globally, powered by AI diagnostics, clinical wearables, and integrated health APIs. In 2026, Femtech will shift from reactive tracking to proactive, personalised health management – covering pregnancy, menopause, and autoimmune conditions.

“The UK is emerging as a key hub, supported by the government’s Women’s Health Strategy and new research from the Royal College of Obstetricians and Gynaecologists outlining top priorities. Investors are bullish, with startups eyeing IPOs amid rapid AI adoption, signalling both financial opportunity and cultural change. Women’s health tech is evolving from simple tracking to predictive coaching.

“Three trends dominate globally: AI-driven symptom analysis predicting issues before they arise; fertility and pregnancy apps transforming into real-time health coaches; and seamless integration of wearable data into healthcare systems. Devices like the Oura Ring and continuous glucose monitors promise actionable insights on cycles, hormones, and fertility.

“Challenges remain – fertility solutions thrive, but menopause, sexual health, and non-hormonal contraception lag due to funding gaps. Sustained investment and cross-sector collaboration are vital to ensure innovation benefits all aspects of women’s health.”

Alisa Sydow, Associate Professor Entrepreneurship at ESCP Business School

“FemTech is entering a period of accelerated growth and recognition. After years of underfunding, the sector is backed by compelling economic evidence. A recent McKinsey report shows that for every $1 invested in women’s health, about $3 is projected in economic growth, highlighting the vast potential of closing the gender health gap[1].

“In 2026, we will see an expansion of holistic, data-driven women’s health platforms that integrate menstrual, fertility, menopause, and mental-health insights into continuous, personalised care. With the NHS opening more digital pathways, collaborations between FemTech start-ups and public healthcare providers will increase.

“We will also see the rise of specialised acceleration programmes, such as The Northern FemTech and Women’s Health Tech Accelerator, designed to fast-track innovation, clinical validation, and market access. These programmes signal a maturing landscape and the need for a stronger ecosystem ready to leverage FemTech innovation.

“Demand for menopause solutions, employer-backed women’s health benefits and products designed for underrepresented groups will continue to grow. At the same time, investor appetite will evolve, as more funds recognise women’s health as one of the most overlooked, high-return opportunities of the decade.

“The UK in 2026 is poised for smarter, more inclusive and economically transformative FemTech innovation.”

Dr Laura Geige, Medical Director at It’s Me & You

“The most significant shift we will witness is FemTech moving emphatically beyond reproductive cycles and towards holistic healthspan optimisation. By 2026, the industry will transition from generalized diagnostics to hyper-personalised, preventative care, leveraging sophisticated AI-driven biomarkers.

“From an aesthetic and medical perspective, we will see the true emergence of the ‘clinic-at-home’ model, where consumer devices seamlessly integrate with professional oversight.

“The core prediction is clear. FemTech success in 2026 will be defined by data depth and privacy-first personalisation.”

For any questions, comments or features,��please contact us directly.

Sophie Bruce, Founder and CEO at MOLO

“The FemTech industry is entering a defining phase in 2026, driven by two powerful forces: growing investor appetite for women’s health and increasing recognition that the mental load carried by mothers is both a wellbeing issue and a major economic drag.

“In 2026, three shifts will stand out. First, the scope of FemTech itself is expanding. Solutions that improve daily life for women, including those that reduce cognitive and emotional labour, are now seen as core to the sector.

“Second, infrastructure will outperform intervention. Tools that simplify logistics and administration will scale faster than consumer wellness apps.

“Third, employer backed models that generate strong data and clear return on investment will dominate.

“Founders who solve real and often overlooked problems such as unpaid labour, decision fatigue and fragmented care pathways will attract the most attention. The winners in 2026 will build evidence informed products that support women in the everyday realities of work and life.”

Nancy Scotford, Co-Founder at Get Rude

“Femtech in 2026 will be defined by hardware emerging as the new competitive advantage. As LLMs commoditise software, companies that combine intelligent devices with strong early distribution are creating something software alone cannot replicate: unique, high-resolution data.

“Despite economic headwinds and talk of an AI bubble, wellness spending remains resilient, echoing the historically recession-proof nature of the sex and intimate industry.

“As a result, 2026 will push femtech further into previously taboo areas, sexual wellness, hormonal optimisation, and menstrual health.

“Ethical data stewardship will become a defining expectation, with inclusive, privacy-first models crucial to unlocking femtech’s projected £130bn potential.”

Sonja Rincón, CEO and Co-Founder at Menotracker

“2026 will be the year femtech’s privacy crisis reaches breaking point. The industry faces an uncomfortable truth: apps are farming out sensitive data, and women are catching on.

“Privacy policies mean nothing when companies still hold the keys to identifiable user data.

“Companies that can’t guarantee anonymity will haemorrhage users. The market projection assumes women keep trusting femtech with their secrets. That trust is already gone.”

Ariane Marie, Founder in FemFinTech

“Like FinTech for women, there’s clearly a growing interest from both the public and the industry to improve products and experiences designed specifically for women – this includes FemTech.

“But despite all this attention, investors often underfund female founders, especially when building solutions for women.

“My hope for 2026 is that women step up to support women-led ventures, by using their products, referring them to friends, and amplifying their work.

“If we want better FemTech products and services, we need to fund the women building them. Together, our choices can help female founders survive and thrive in a landscape that too often overlooks them.”

For any questions, comments or features,��please contact us directly.

The post Expert Predictions For FemTech In 2026 appeared first on 91̽��.

This makes it an incredibly interesting sector to keep an eye on, especially as tech starts to help women navigate areas of their health and wellbeing that were previously ignored.

What Does FemTech Cover?

FemTech, short for “female technology” is used to describe products, services and apps designed specifically for women’s health and wellness. Typically, this covers things like:

• Menstrual health, including period tracking apps and devices, sustainable menstrual products and smart devices that can help with pain management.
• Pregnancy planning, including at home hormone testing, fertility trackers and products to help the body have the right vitamins it needs during this time.
• Sexual health, including easier STD testing, libido tracking and tech-driven contraceptive options.
• Support with menopause, which includes devices to help with symptoms, symptom trackers and online therapy for any emotional elements.
• Support with mental wellbeing, such as therapists specifically for women, vitamins and mental health trackers.

To help us figure out what 2025 might have in store for this sector, we asked the experts. Here’s what they had to say..

Our Experts

• Valentina Milanova, Founder & CEO of Daye
• Mayra Hurtado, CEO of Hormony
• Kanika Mishra Pathak, Lead R&D Director at MHA
• Jennifer Pfau, FemTech Advocate and CEO at pFocus Marketing
• Caroline MacDonald, Founder & CEO of Oggadoon

Valentina Milanova, Founder & CEO of Daye

“As we look ahead to 2025, I believe femtech will play a crucial role in advancing women’s health and closing critical care gaps. At Daye, we’re particularly focused on supporting the NHS’s goal of eradicating cervical cancer by 2040 through our non-invasive, at-home HPV screening solution. This technology will make regular screening more accessible and convenient, helping to detect high-risk HPV infections early and reducing the incidence of cervical cancer.

“Beyond cervical health, I predict we’ll see a surge in personalised, tech-enabled care solutions addressing historically underserved areas of vaginal, menstrual and hormonal health. Daye’s virtual nurse and OBGYN consultations aim to support the 700,000 women currently on gynaecological health waiting lists in the UK.

“Importantly, increased investment in femtech could yield significant economic benefits. Research shows that for every additional £1 invested in obstetrics and gynaecology services per patient in England, there’s a potential £11 return. By 2025, I expect we’ll see more recognition of how supporting female health drives broader societal and economic gains.

“Ultimately, femtech in 2025 will be about leveraging technology to provide more accessible, personalised care while simultaneously addressing systemic gaps in women’s healthcare.”

Mayra Hurtado, CEO of Hormony

“In 2025, femtech will continue on its trajectory as a transformative force in the global economy: reshaping industries, boosting workforce efficiency, and creating entirely new markets. Beyond its projected $60 billion market valuation, femtech’s innovations will catalyse growth in biotechnology, wearable technology, and AI-driven preventive healthcare, leading to cascading economic benefits across sectors.

“The integration of real-time biometric monitoring through wearable devices, paired with AI that can predict and prevent health crises, will drastically reduce the economic burden of untreated women’s health conditions. For instance, precision care in areas like endometriosis and reproductive health could save billions annually in healthcare costs while increasing workforce participation. It’s likely that Governments will recognise femtech solutions in public health policies, creating massive procurement opportunities and driving down healthcare disparities, whilst relieving pressure on healthcare services.

“As femtech products become more ubiquitous and accessible, global supply chains will be reshaped: from hormonal biosensors embedded in consumer electronics to telehealth platforms accessible even in low-bandwidth regions. Emerging markets will benefit from femtech’s expansion, as affordable, smartphone-compatible diagnostics empower millions of women, unlocking $1 trillion in untapped economic potential by enabling their full participation in education and the workforce.

“In 2025, femtech will not just enhance healthcare—it will continue to redefine global economic priorities, elevate women’s participation in society and the economy, and improve the lives of all humans. By advancing gender-specific health, femtech will unlock a deeper understanding of the full spectrum of human health, providing insights that benefit all genders. This holistic approach will become the cornerstone of sustainable development and drive unprecedented innovation worldwide, in 2025 and beyond.”

Kanika Mishra Pathak, Lead R&D Director at MHA

“2025 is likely to be a major year for femtech, thanks to a number of changes which are set to bring a wave of fresh investment to the industry. These include £6.1 billion of funding for research in sectors including medical science announced in the budget; the creation of pension ‘megafunds’ designed to boost investment in high growth industries like femtech; and the arrival of a new industrial strategy, which will prioritise growth and investment in industries with untapped potential, a category femtech fits squarely in.

“AI is also accelerating the pace of major technological developments on issues such as breast cancer treatment, IVF embryo assessment and maternal healthcare. We can expect to see significant developments in these areas across the year. The area that is likely to see the biggest advances is wearables, which is becoming a very competitive sector as the market is growing fast and proving particularly popular with women. This is leading several major manufacturers to improve their devices functionality when it comes to women’s health, often through partnerships with and acquisitions of specialist women’s health and menopause technology companies.�� Expect to see a lot more of this in 2025 as women’s health is put at the front and centre of wearables product development.”

Jennifer Pfau, FemTech Advocate and CEO at pFocus Marketing

“The U.S. femtech industry is poised for transformative growth by 2025, driven by shifting regulatory landscapes. With Republican-led governments often favouring deregulation, the reduced bureaucratic barriers could open doors for innovation across women’s health technology. Startups and established firms alike could benefit from streamlined FDA approval processes and relaxed telemedicine restrictions, expediting the launch of cutting-edge products.

“The easing of restrictions on research and commercialization may also drive breakthroughs in previously underserved areas like menopause management, pelvic health, and endometriosis treatments.

“Deregulation might promote private investment, as venture capitalists (VCs) are drawn to markets with fewer policy-driven bottlenecks. With the continual call for more women-led VCs, the potential influx of capital could accelerate the adoption of AI and data-driven technologies, enabling more personalized health solutions.

“However, the industry will likely face heightened scrutiny from advocacy groups concerned about consumer protection and equitable access. While a Republican-led U.S. government may prioritize deregulation, fostering rapid innovation, this could inspire other nations to reevaluate their policies to remain competitive in the global market. Countries with historically rigid healthcare regulations, such as those in Europe, might begin to adopt more flexible approaches, accelerating approvals for cutting-edge femtech solutions.”

Caroline MacDonald, Founder & CEO of Oggadoon

“Femtech continues to captivate startups and investors alike, showing remarkable growth potential. With increasing waiting lists for medical services, conflicting online advice, and the risk of GP surgeries closing—especially in rural communities— people are becoming more proactive about monitoring their health. More celebrities are opening up about their health journeys on social media, shining a light on the importance of personal well-being. However, a significant challenge remains: most research still overlooks the complexities of the female body

“In 2025, there will be increased resources for managing menopause and perimenopause symptoms, offering holistic approaches to improve quality of life. In the workplace, we are witnessing a growing trend towards support systems for navigating menopause, with technology set to play an increasingly important role in this transformation. Also, demand to monitor general menstrual cycles, and the rise of Gen-Z, who need to understand their hormones more than ever.

“Moreover, maternal care initiatives will expand to provide comprehensive support throughout pregnancy and postpartum periods. This includes access to mental health resources and nutritional guidance aimed at empowering mothers with the knowledge they need. Breastfeeding, sleep deprivation or the fourth trimester is often not discussed with new mothers, and they need to know these are normal experiences and shared by many.

“At Oggadoon we are an all-female team, and are deeply committed to raising awareness about these products and making a meaningful impact. Female health is finally getting the attention it deserves, and the tech companies are maximising this.”

For any questions, comments or features,��please contact us directly.

The post Expert Predictions For FemTech in 2025 appeared first on 91̽��.

Founded in 2016 and based in London, 91̽�� is where decision-makers, investors and startups of all sizes come to find out the latest developments and trends within the industry.��

91̽�� are delighted to announce our first ever FemTech44 roundup, celebrating the U.K. and Europe’s most innovative FemTech companies.

Thank you to our judges Ale Madio (Tommee Tippee) and Lara Dolden (Techround) for your time and effort to confirm our list of outstanding finalists.

Feedback From The Judges

“Being a judge for the Femtech awards was an eye-opening experience and a privilege. Learning about all these fantastic companies and start-ups focusing on women’s health and well-being made me feel hopeful about women’s future generations.”

– Ale Madio, Senior Global Product Marketing Manager at Tommee Tippee

“It has been incredible to see the tools and resources being offered to women, allowing them to have power over their bodies. Whether it’s to stay on top of their health, manage their hormones or even take control of their own pleasure, it’s heartening to see the creativity and the innovation in the FemTech space.”

– Lara Dolden, Senior Writer, 91̽��

See The List

Top 10 – See Here >>

Top 25 – See Here >>

Top 44 – See Here >>

For any questions, comments or features,��please contact us directly.

Thank You To Our Judges!

For any questions, comments or features,��please contact us directly.

The post Announced! FemTech44 Winners 2023 appeared first on 91̽��.

Founder: Dr. Georgie Bruinvels

Website:
 
 

 

About FitrWoman

 
FitrWoman is a UK-based femtech company that offers a sports nutrition app designed specifically for women. The company was founded by Dr. Georgie Bruinvels, an internationally recognized researcher in the field of women’s health and exercise physiology, with the aim of providing female athletes with tailored nutritional advice and support around their menstrual cycle.

FitrWoman’s app is based on the latest scientific research on female physiology and nutrition, and offers a range of features designed to help women optimize their sports performance and recovery. These include personalised nutritional advice and meal plans, as well as insights into the menstrual cycle and how it affects exercise and nutrition.

In addition to its nutritional features, FitrWoman’s app also includes tools to help women manage their training and recovery. This includes workout tracking, injury prevention advice, and recovery tips to help women stay on top of their game.

FitrWoman’s app is designed to be user-friendly and accessible to women of all ages and fitness levels. The company works closely with female athletes and sports teams to ensure that its app is tailored to the unique needs and challenges of women in sport.
 
 

The post 29. FitrWoman appeared first on 91̽��.

Founders: Sophie Blythe, Antonia Burridge & Isobel Burlington

Website:
 
 

 

About Koala & Joe

 
Expert help for mums. Koala & Joe is a new nationwide platform connecting mums with trusted experts.

The site enables parents to find and book virtual or in person sessions with verified experts across a variety of fields – from doulas to dieticians, pelvic health physios to sleep coaches & more.

Founded by 3 mums, Koala & Joe helps mums (& dads) get the expert help they need, when they need it. A digital-age alternative to long NHS referral times and Dr Google. Plus 1% of revenue goes to support vulnerable UK families.
 
 

The post 42. Koala & Joe appeared first on 91̽��.

Founder: Nicole Dahlstrom

Website:
 
 

 

About FemTech Collective

 
Femtech Collective is a global community of femtech founders, investors, and supporters that is dedicated to driving innovation in women’s health. The organisation was founded in 2018 and has since grown to become a leading voice in the femtech industry, advocating for increased investment and innovation in women’s health.

Femtech Collective offers a range of resources and support to its members, including mentorship, networking opportunities, and access to funding. The organisation also hosts events and conferences to bring together femtech leaders and innovators from around the world to share knowledge, ideas, and best practices.

One of the key goals of Femtech Collective is to increase awareness and education around women’s health issues, including reproductive health, menstrual health, and menopause. By driving innovation in these areas, Femtech Collective aims to improve the overall health and wellbeing of women around the world.
 
 

The post 30. FemTech Collective appeared first on 91̽��.

Founder: Hilla Shaviv

Website:
 
 

 

About Gals Bio Ltd

 
The monthly bleeding experienced by half of the world population for 40 years is still a neglected arena that is hardly investigated or funded for innovations. At the same time, women’s health devices are expensive, cumbersome and hard to use.

Since 2016 Gals Bio has been developing Tulipon – a new generation of vaginal devices for women.

Tulipon will completely disrupt the feminine hygiene, wellness and health markets by providing a safe, reliable, easy-to-use, sustainable holistic hygiene device that can also monitor and screen a person’s health and wellness.
 
 

The post 23. Gals Bio Ltd appeared first on 91̽��.

Founder: Colette Courtion

Website:
 
 

 

About Joylux

 
Joylux is a UK-based femtech company that specialises in developing non-invasive intimate wellness products for women. Founded by Colette Courtion in 2017, the company aims to provide women with innovative solutions for common vaginal health issues such as urinary incontinence, vaginal dryness, and sexual dysfunction.

Joylux’s flagship product is the vFit, a device that uses red light therapy to improve vaginal health and wellness. The vFit is designed to be used in the privacy of one’s own home and is clinically proven to help with issues such as vaginal dryness, painful intercourse, and low libido.

In addition to the vFit, Joylux also offers a range of other intimate wellness products such as the Joylux Vibrance, a personal handheld device for improving pelvic floor strength and reducing incontinence, and the Joylux Afterglow, a non-invasive laser treatment for improving vaginal health and function.

Joylux is committed to empowering women by providing them with safe and effective solutions for intimate wellness. The company works closely with healthcare providers and industry experts to ensure that its products are backed by science and are of the highest quality.
 
 

The post 10. Joylux appeared first on 91̽��.